BNC Korea Co., Ltd. (KOSDAQ:256840)

Market Cap	309.14B +10.8%
Revenue (ttm)	98.11B +12.9%
Net Income	13.76B -8.3%
EPS	201.77 -9.4%
Shares Out	68.39M
PE Ratio	22.38
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	744,575
Average Volume	1,630,294
Open	4,600.00
Previous Close	4,605.00
Day's Range	4,500.00 - 4,635.00
52-Week Range	3,475.00 - 6,310.00
Beta	0.66
RSI	38.59
Earnings Date	Mar 20, 2026

About BNC Korea

BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia. It also provides HA fillers ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 250
• Stock Exchange: KOSDAQ
• Ticker Symbol: 256840

Financial Performance

In 2024, BNC Korea's revenue was 89.23 billion, an increase of 10.16% compared to the previous year's 81.00 billion. Earnings were 13.31 billion, a decrease of -48.19%.